{"id":36499,"date":"2026-03-18T11:19:00","date_gmt":"2026-03-18T15:19:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=36499"},"modified":"2026-03-08T13:48:32","modified_gmt":"2026-03-08T17:48:32","slug":"turn-abandoned-patents-into-profit","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/turn-abandoned-patents-into-profit\/","title":{"rendered":"Turn Abandoned Patents Into Profit"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

The pharmaceutical industry operates on a high-risk model where the cost of a single drug approval ranges from $1 billion to $2.6 billion.1<\/sup> While legal teams spend years building patent fortresses around these assets, the lifecycle of intellectual property is frequently cut short by the owners themselves. A majority of U.S. patents are abandoned before they reach their full statutory term.1<\/sup> This process, known as strategic abandonment, represents a calculated extraction of value and a reallocation of finite resources rather than a simple failure of innovation.<\/p>\n\n\n\n

The Architecture of Strategic Abandonment<\/strong><\/p>\n\n\n\n

Strategic abandonment is the elective termination of intellectual property rights before their legal expiration. In the pharmaceutical sector, this occurs through two primary mechanisms. The first is the express abandonment of a patent application during the prosecution phase.1<\/sup> The second is the failure to pay escalating maintenance fees for a granted patent, causing it to lapse and enter the public domain.3<\/sup><\/p>\n\n\n\n

The industry classifies abandonment into specific types based on the underlying economic rationale. Commercial abandonment happens when a work is no longer viable to maintain. Strategic abandonment occurs when an owner replaces an older edition or technology with a newer version to migrate a customer base and preserve a monopoly.4<\/sup> Temporary abandonment describes a scenario where an owner suspends availability to restore commercial value later or reduce marketing costs.4<\/sup><\/p>\n\n\n\n

Economic analysis suggests that the efficient solution to abandonment varies by type.4<\/sup> For the strategist, an abandoned patent application is a detailed map of a competitor\u2019s R&D path.1<\/sup> It reveals technological bets, strategic pivots, and cost-benefit calculations that were once hidden behind the veil of corporate secrecy.<\/p>\n\n\n\n

Maintenance Fees as Economic Filters<\/strong><\/p>\n\n\n\n

Maintenance fees function as a property tax on innovation. Governments grant temporary monopolies in exchange for public disclosure, but patent holders must periodically pay to maintain these rights.3<\/sup> These fees are designed to cull the “patent thicket” by forcing owners to re-evaluate the commercial worth of their assets at specific intervals.3<\/sup><\/p>\n\n\n\n

In the United States, utility patents are subject to a staggered fee schedule. Payments are due at 3.5 years, 7.5 years, and 11.5 years after the patent grant.1<\/sup> These fees escalate significantly at each stage. This system forces a “keep or drop” decision at moments that often coincide with clinical development milestones.3<\/sup><\/p>\n\n\n\n

USPTO Maintenance Fee Interval<\/strong><\/td>Standard Entity Fee (2024)<\/strong><\/td>Small Entity Fee (2024)<\/strong><\/td>Micro Entity Fee (2024)<\/strong><\/td><\/tr>
3.5 Years<\/td>$2,150<\/td>$860<\/td>$430<\/td><\/tr>
7.5 Years<\/td>$4,040<\/td>$1,616<\/td>$808<\/td><\/tr>
11.5 Years<\/td>$8,280<\/td>$3,312<\/td>$1,656<\/td><\/tr>
Late Surcharge (Grace Period)<\/td>$540<\/td>$216<\/td>$108<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

5<\/sup><\/p>\n\n\n\n

The data released by the USPTO shows a consistent rate of decay in patent maintenance over time. Approximately 86% of issued patents survive the first maintenance hurdle at 3.5 years. This drops to 67% at the 7.5-year mark and falls to just 44% at the final 11.5-year interval.6<\/sup> For a pharmaceutical firm, missing these deadlines leads to immediate expiration, allowing competitors to enter the market.3<\/sup><\/p>\n\n\n\n

The Global Maintenance Fee Maze<\/strong><\/p>\n\n\n\n

Managing a global pharmaceutical patent portfolio requires navigating a non-harmonized system of deadlines, currencies, and local regulations.3<\/sup> While the U.S. uses a staggered schedule, many other jurisdictions employ annual systems.<\/p>\n\n\n\n

In Canada, maintenance fees are due annually starting from the second anniversary of the filing date until the nineteenth.5<\/sup> The fees increase in tiers as the patent ages.<\/p>\n\n\n\n

Canadian Anniversary Tier<\/strong><\/td>Standard Entity Fee (CAD, 2025)<\/strong><\/td>Small Entity Fee (CAD, 2025)<\/strong><\/td><\/tr>
2nd to 4th Anniversaries<\/td>$130.50<\/td>$58.68<\/td><\/tr>
5th to 9th Anniversaries<\/td>$289.19<\/td>$104.40<\/td><\/tr>
10th to 14th Anniversaries<\/td>$362.27<\/td>$130.50<\/td><\/tr>
15th to 19th Anniversaries<\/td>$651.46<\/td>$264.13<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

5<\/sup><\/p>\n\n\n\n

The European Patent Office (EPO) requires annual renewal fees starting from the third year after filing, even while the application is still pending.3<\/sup> Once a patent is granted and validated in member states, owners must pay separate annual fees to each national office.3<\/sup> This administrative burden often leads firms to abandon patents in smaller markets where the maintenance cost exceeds the local market potential.3<\/sup><\/p>\n\n\n\n

In jurisdictions like Japan and South Korea, fees are determined by the total number of claims in the patent.7<\/sup> This creates a direct incentive for firms to delete redundant claims or consolidate them to reduce costs.7<\/sup> Russian Federation fees for examination are similarly tied to the number of independent claims.7<\/sup><\/p>\n\n\n\n

Translation Costs and Geographic Abandonment<\/strong><\/p>\n\n\n\n

Translation costs represent one of the largest financial drains on a global patent strategy. These expenses are incurred during filing, prosecution, and validation in jurisdictions where English is not an official language.7<\/sup> In countries like China, Japan, or Russia, translation can account for 75% to 80% of total filing costs.7<\/sup><\/p>\n\n\n\n

Estimated translation costs for a single application typically range between $3,000 and $6,500.7<\/sup> To manage these burdens, companies often focus their protection on English-language jurisdictions or regional blocs that share a common language, such as Latin America.7<\/sup> Some countries, including Brazil, Germany, Italy, and the UK, offer discounted maintenance fees for owners who declare an intention to license their patent to third parties.7<\/sup><\/p>\n\n\n\n

The Clinical Trial Graveyard<\/strong><\/p>\n\n\n\n

The primary driver of blockbuster drug abandonment is clinical failure. Only 9.6% of drugs that enter Phase I testing eventually reach the market.2<\/sup> For cardiovascular agents, the success rate is even lower, with only 6.6% advancing to approval.2<\/sup><\/p>\n\n\n\n

Phase II represents the first time a drug is tested in actual patients, making it a critical point for determining future costs.2<\/sup> It is also the stage where the highest rate of attrition occurs. Approximately 28% to 30% of programs successfully complete Phase II.2<\/sup><\/p>\n\n\n\n

Reason for Phase II Failure<\/strong><\/td>Percentage of Attrition<\/strong><\/td><\/tr>
Unknown toxic side effects<\/td>50%<\/td><\/tr>
Insufficient efficacy<\/td>30%<\/td><\/tr>
Poor commercial viability<\/td>15%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

2<\/sup><\/p>\n\n\n\n

Even after a drug passes Phase II, the risk remains high. More than 58% of drugs that enter Phase III fail to progress to the market.2<\/sup> These late-stage failures are catastrophic for R&D productivity measures because Phase III is the most expensive part of the development cycle.2<\/sup><\/p>\n\n\n\n

The Statistical Trap of False Discoveries<\/strong><\/p>\n\n\n\n

The high rate of Phase III failure is often rooted in the statistical limitations of Phase II trials. A positive result in Phase II, which typically utilizes a small sample size and homogeneous patient population, is a poor predictor of Phase III success.2<\/sup><\/p>\n\n\n\n

Statistical phenomena known as the False Discovery Rate (FDR) mean that a positive result in Phase II with a p-value of 0.05 has a 23% to 50% chance of being a false positive.2<\/sup> Phase III trials involve larger, less homogeneous populations that reflect real-world clinical settings.2<\/sup> This increased complexity often reveals that the efficacy observed in earlier stages does not translate to a broader patient base.2<\/sup><\/p>\n\n\n\n

The probability of unexpected failure due to a lack of efficacy in Phase III is estimated at approximately 14%.10<\/sup> This rate of unexpected failure results in nearly 270,000 patients undergoing Phase III trials every year for treatments that ultimately prove ineffective.10<\/sup><\/p>\n\n\n\n

Real Options and the Mathematics of the Quit<\/strong><\/p>\n\n\n\n

Modern pharmaceutical management uses real options theory to decide when to walk away from a project. Unlike traditional methods that treat investment as an all-or-nothing strategy, real options account for managerial flexibility.11<\/sup> Management has the ability to create, execute, or abandon strategic options as uncertainty becomes known over time.11<\/sup><\/p>\n\n\n\n

An R&D project is a “call option” on a future revenue stream. The abandonment option acts as a “put option,” protecting the firm against downside risk.12<\/sup> If drilling results or clinical data are disappointing, the firm can abandon the project and minimize further sunk costs.12<\/sup><\/p>\n\n\n\n

The framing of these problems is half the challenge. Analysts estimate that 50% of the real options task is thinking about the problem, 25% is the modeling, and 25% is explaining the results to management.13<\/sup> This approach allows firms to treat R&D investments as a series of staged bets rather than a single, massive gamble.<\/p>\n\n\n\n

Case Study: The Torcetrapib Mortality Crisis<\/strong><\/p>\n\n\n\n

The abandonment of Pfizer’s torcetrapib remains a definitive example of a late-stage safety failure. Torcetrapib was a cholesteryl ester transfer protein (CETP) inhibitor designed to increase high-density lipoprotein (HDL) cholesterol.14<\/sup> It was intended to replace revenue from Lipitor, which was nearing its own patent expiration in 2010.15<\/sup><\/p>\n\n\n\n

Phase II trials were successful, showing that torcetrapib increased HDL by 46% to 106% in a dose-dependent manner.14<\/sup> However, on December 3, 2006, Pfizer halted the Phase III ILLUMINATE trial.14<\/sup> An independent monitoring board discovered that patients taking the torcetrapib and atorvastatin combination had an increased risk of death compared to those taking atorvastatin alone.15<\/sup><\/p>\n\n\n\n

ILLUMINATE Trial Group<\/strong><\/td>Number of Deaths<\/strong><\/td><\/tr>
Torcetrapib + Atorvastatin<\/td>82<\/td><\/tr>
Atorvastatin alone<\/td>51<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

14<\/sup><\/p>\n\n\n\n

Pfizer had spent over $800 million on torcetrapib\u2019s development.15<\/sup> The decision to abandon the drug was immediate and global. This withdrawal was necessary to avoid a larger tragedy and the litigation costs associated with keeping a dangerous drug on the market.14<\/sup><\/p>\n\n\n\n

Case Study: Omarigliptin and the Market Pivot<\/strong><\/p>\n\n\n\n

Merck\u2019s abandonment of omarigliptin demonstrates that even clinically successful drugs can be strategically discarded. Omarigliptin is a once-weekly DPP-4 inhibitor for type 2 diabetes that was approved in Japan in 2015.19<\/sup> In 2016, Merck announced it would not submit marketing applications for the drug in the U.S. or Europe.20<\/sup><\/p>\n\n\n\n

Merck stated the decision was for “business reasons” and not related to safety or efficacy.20<\/sup> Analysts point to a shifting competitive landscape. Other classes of diabetes medications, specifically SGLT2 inhibitors like Jardiance and GLP-1 products like Victoza, had released data showing they reduced cardiovascular death.22<\/sup><\/p>\n\n\n\n

DPP-4 inhibitors generally do not reduce cardiovascular risk. Merck likely calculated that a once-weekly dosing advantage was not enough to overcome the lack of heart-health benefits in a market increasingly focused on cardiovascular outcomes.19<\/sup> They pivoted their investment toward other projects, including their own SGLT2 prospect, ertugliflozin.19<\/sup><\/p>\n\n\n\n

Route of Administration as a Death Sentence<\/strong><\/p>\n\n\n\n

Routes of administration can determine the commercial life of a patent. Pfizer\u2019s Exubera, an inhaled insulin, was launched with expectations that it would revolutionize diabetes care by eliminating the need for needles.24<\/sup> The product failed, capturing less than 1% of the insulin market and leading to a $2.8 billion write-off.24<\/sup><\/p>\n\n\n\n

The failure was attributed to a misjudgment of patient behavior. The delivery device was excessively large, leading patients to nickname it “the bong”.24<\/sup> Prescribers faced “access friction” because the drug required regular lung function monitoring.24<\/sup><\/p>\n\n\n\n

A similar dynamic occurred with Relenza (zanamivir), an inhaled flu drug from GSK. Although effective, it lost the market to Roche\u2019s Tamiflu, which was a pill.24<\/sup> The Relenza inhaler was difficult for patients with respiratory flu symptoms to use. These cases illustrate that the logistical and psychological “switching cost” for patients and doctors can lead to the abandonment of even effective drugs.24<\/sup><\/p>\n\n\n\n

The 2026-2030 Patent Super-Cliff<\/strong><\/p>\n\n\n\n

The pharmaceutical industry is approaching a period of tectonic revenue erosion. Between 2025 and 2030, over $300 billion in prescription drug revenue will lose exclusivity.9<\/sup> This represents the largest concentrated patent cliff in history.9<\/sup><\/p>\n\n\n\n

Drug Asset<\/strong><\/td>Primary Manufacturer<\/strong><\/td>Estimated Revenue at Risk<\/strong><\/td>Projected Expiration<\/strong><\/td><\/tr>
Keytruda<\/td>Merck<\/td>>$25 Billion<\/td>2028<\/td><\/tr>
Eliquis<\/td>BMS \/ Pfizer<\/td>>$10 Billion<\/td>2026-2028<\/td><\/tr>
Stelara<\/td>J&J<\/td>>$9 Billion<\/td>2023-2025<\/td><\/tr>
Humira<\/td>AbbVie<\/td>>$20 Billion<\/td>2023 (Ongoing)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

26<\/sup><\/p>\n\n\n\n

For five of the top ten pharmaceutical firms, the assets at risk represent more than 50% of their total revenue.26<\/sup> This creates intense pressure to maximize revenue before expiration through lifecycle management or to fill the financial vacuum through mergers and acquisitions.26<\/sup><\/p>\n\n\n\n

Evergreening and Defensive Innovation<\/strong><\/p>\n\n\n\n

To mitigate the impact of the patent cliff, companies employ “evergreening” strategies. This involves filing numerous secondary patents to extend the period of market exclusivity beyond the original 20-year term.28<\/sup><\/p>\n\n\n\n

These secondary patents cover various aspects of the drug, including its formulation, method of use, manufacturing processes, or delivery devices.28<\/sup> Strategists look for “formulation flurries”\u2014a sudden increase in patent filings related to new delivery systems\u2014as a signal that a competitor is preparing to migrate its patient base to a new, protected version of the drug.24<\/sup><\/p>\n\n\n\n

The goal is to move patients from a tablet that is about to go off-patent to a new subcutaneous or long-acting version.24<\/sup> If the brand-name company can patent-protect the new format, they can leave generic competitors fighting over a shrinking market for the old version.24<\/sup><\/p>\n\n\n\n

The Inflation Reduction Act and the Biosimilar Paradox<\/strong><\/p>\n\n\n\n

The Inflation Reduction Act (IRA) has fundamentally altered the competitive landscape for pharmaceutical IP. The act gives the government power to negotiate prices for top-selling drugs, which can suppress the price before a biosimilar even enters the market.24<\/sup><\/p>\n\n\n\n

This creates a “Biosimilar Paradox.” Historically, biosimilars gained market share by offering a discount against the high-priced brand.31<\/sup> If the brand\u2019s price is already negotiated down by the government, the “spread” available for the biosimilar to undercut shrinks.31<\/sup> This may cause companies to abandon biosimilar candidates targeting drugs likely to be negotiated, as the risk profile increases and the potential for a return on investment decreases.31<\/sup><\/p>\n\n\n\n

M&A as a Tool for Strategic Pruning<\/strong><\/p>\n\n\n\n

Patent expirations are a primary driver of industry-wide mergers and acquisitions (M&A). Blockbuster drugs generate massive cash flow that firms use to acquire late-stage, de-risked assets to offset their own patent cliffs.26<\/sup><\/p>\n\n\n\n

When companies merge, they often focus on core competencies and “get rid of assets” that have less importance for global competition.29<\/sup> In 2015, Novartis purchased GSK\u2019s oncology business while GSK took over Novartis\u2019s vaccine business.29<\/sup> This type of strategic swap leads to the abandonment or out-licensing of compounds that no longer fit the new corporate R&D focus.29<\/sup><\/p>\n\n\n\n

Operational Risks of Spreadsheet Tracking<\/strong><\/p>\n\n\n\n

A significant portion of the industry still relies on manual tools like Microsoft Excel to manage patent portfolios.32<\/sup> This creates a systemic operational risk. The complexity of tracking patent expiration dates, which involves factoring in the 20-year term, filing dates, Patent Term Adjustments (PTA), and Patent Term Extensions (PTE), leads to an inevitability of human error.32<\/sup><\/p>\n\n\n\n

A portfolio manager tracking fifty drugs with five patents each can easily exceed hundreds of interrelated data points.32<\/sup> Spreadsheet tracking is a “pull” method of intelligence, requiring the user to manually check for updates.32<\/sup> If a maintenance fee is missed or a Paragraph IV challenge is filed, the spreadsheet remains green and compliant until the user intervenes.32<\/sup> This latency can lead to accidental abandonment, which is akin to “constructing a headquarters on a known seismic fault line”.1<\/sup><\/p>\n\n\n\n

Using DrugPatentWatch for Competitive Intelligence<\/strong><\/p>\n\n\n\n

Platforms like DrugPatentWatch transform complex patent data into actionable competitive intelligence. They provide real-time alerts on patent expirations, litigation histories, and changes in exclusivity status.33<\/sup><\/p>\n\n\n\n

Analysts use these tools to monitor “stealth” patents that are not listed in the FDA Orange Book, such as manufacturing process patents.24<\/sup> By tracking competitor abandonment in real-time, companies can identify “white space” opportunities for their own R&D or prepare commercial countermeasures to generic challenges.24<\/sup><\/p>\n\n\n\n

Key Takeaways<\/strong><\/p>\n\n\n\n